AKT1 and cholangiocarcinoma: Currently, there are clinical trials on CCA therapies that separately target PI3K, AKT, and mTOR, such as the PI3K inhibitors copanlisib and BKM120, AKT inhibitor MK2206, and mTOR inhibitor everolimus [60].